Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

April 1, 2013

Study Completion Date

April 1, 2013

Conditions

Schizophrenia

Interventions

DRUG

SPD489 40mg

Oral administration of 40 mg once-daily for up to 12 weeks

DRUG

SPD489 100mg

Oral administration of 100 mg once-daily for up to 12 weeks

DRUG

SPD489 160mg

Oral administration of 160 mg once-daily for up to 12 weeks

DRUG

Placebo

Oral administration once-daily for 12 weeks

Trial Locations (1)

University Hills Clinical Research, Irving